Lv1
34 积分 2024-09-11 加入
Safety of the oral factor Xla inhibitor asundexian comparedwith apixaban in patients with atrial fbrillation(PACIFIC-AF): a multicentre, randomised, double-blind,double-dummy, dose-fnding phase 2 study
4个月前
已完结
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial
4个月前
已完结
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
4个月前
已完结
Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent:results of a phase 3, double-blind, randomized study(ASPIRE Ⅱ)
6个月前
已完结
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
8个月前
已完结
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
8个月前
已完结
Routes to molecular glue degrader discovery
8个月前
已完结
Acute Respiratory Distress Syndrome Advances in Diagnosis and Treatment
9个月前
已完结
Time for united action on depression: a Lancet-World Psychiatric Association Commission
10个月前
已完结
皖公网安备34019202002308
